Prime Therapeutics

Don’t let your tools to curb the opioid epidemic go to wasteNew public opinion survey about opioid use from Prime Therapeutics has surprising results.
Brace for a barrage of biosimilarsThe next few years will see the healthcare industry bracing itself for new biosimilar products for a range of illnesses from oncology to rheumatoid arthritis.
Fourteen things Trump needs to know about opioidsAs President Trump promises fight the opioid epidemic, here are 14 things experts want him to know.
Autoimmune drug pipeline: What health execs should watchNew drugs for RA, psoriasis, type 1 diabetes and Crohn’s disease—some recently approved and others coming down the pipeline—could have an impact on the industry.
Drug Spending Slows for Major Pharmacy Benefit Managers
Prescribing practices that increase risk of opioid overdoseTwo studies, one from Prime Therapeutics and Stanford, reveal an alarming increase in overdose with concurrent use of opioids and benzodiazepines. Here’s how managed care can help.
Walgreens and Prime Therapeutics Create Specialty Pharma Mail Firm
Walgreens and Prime Therapeutics Create Specialty Pharma Mail FirmWhat the new company will mean for specialty pharmacy.
Nearly half of BCBS members discontinue this RA drug after 1 yearAnalysis from Prime shows that improvements in persistency, adherence is key in RA treatments.
Health execs must brace for autoimmune drug changesA comprehensive understanding of this rapidly increasing drug class is essential to integrate pharmacy and medical claim information.
Biosimilar approvals deemed “too slow”While FDA’s approval last week of infliximab-dyyb (Inflectra, Celltrion and Hospira), a biosimilar to Remicade (Janssen Biotech) for rheumatoid arthritis, Chron’s disease and other conditions is positive, FDA’s approval pace for biosimilars is too slow, according to a pharmacy benefit manager (PBM).